Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies to elicit an individualized, systemic anti-tumor immune response for cancer patients. The company's engineered viruses are designed to induce immunogenic cell death within the tumor microenvironment, releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the injection site, leading to in-situ immunization against injected and distant metastases. This local administration aims to achieve therapeutic effects while minimizing systemic exposure and toxicity. The company believes viral immunotherapy is a promising cancer treatment modality and seeks to improve patient outcomes by optimizing vectors, transgenes, clinical indications, and product attributes like high-titer formulation and storage conditions ¹.

The company has established two clinical off-the-shelf viral immunotherapy platforms: one based on genetically modified adenovirus and another on herpes simplex virus (HSV) constructs. Its most advanced product candidate, aglatimagene besadenovec (aglatimagene), is an off-the-shelf adenovirus product candidate administered with the prodrug valacyclovir. The lead HSV-based product candidate, linoserpaturev, is being evaluated in an investigator-sponsored phase 1b clinical trial for recurrent high-grade glioma (HGG) ¹.

Candel Therapeutics generates revenue through various license, royalty, and collaboration agreements, under which it licenses patents, patent applications, and other intellectual property. The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future ¹. The company's core business model involves developing and commercializing viral immunotherapies, with a focus on advancing its two most advanced product candidates, aglatimagene and linoserpaturev, for a broad range of solid tumor indications, while also building its pipeline through its enLIGHTEN™ Discovery Platform ¹.

Aglatimagene is a replication-defective adenovirus genetically modified to express the HSV-thymidine kinase enzyme, which activates the prodrug valacyclovir at the tumor site to generate an anti-tumor immune response. It has been administered to over 1,000 cancer patients in more than 10 clinical trials across various solid tumor indications, showing encouraging clinical activity and a favorable tolerability profile in monotherapy and combination settings ¹. The company is currently pursuing indications in lung and prostate cancer for aglatimagene ¹.

Linoserpaturev is a modified HSV engineered for enhanced specificity and tumor cell killing, with replication specifically in Nestin-expressing cancer cells. It is being evaluated in an investigator-sponsored phase 1b clinical trial for recurrent HGG, where it has shown an activity signal in a difficult-to-treat brain cancer population. The HSV-based platform also supports pipeline expansion with novel agents ¹. The enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors, designed to generate both replication-defective and replication-competent agents ¹.

For the fiscal year ended December 31, 2025, Candel Therapeutics reported a net loss of $38.2 million ², compared to a net loss of $55.2 million for the year ended December 31, 2024 ². The company had an accumulated deficit of $230.4 million as of December 31, 2025 ². As of December 31, 2025, cash and cash equivalents were $119.7 million ². The company has no products approved for commercial sale and has not generated any revenue from product sales ².

The company's operating losses have resulted primarily from research and development programs and general and administrative costs ². The net loss for 2025 of $38.2 million ² represents a decrease from the $55.2 million ² net loss in 2024, indicating a reduction in net losses year-over-year. The company expects research and development expenses to significantly increase with ongoing and future clinical trials ².

During the reported fiscal period, Candel Therapeutics announced positive topline data from its pivotal phase 3 clinical trial of aglatimagene in newly diagnosed, localized prostate cancer in intermediate- to high-risk patients in December 2024 ¹. The study met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival (DFS) for aglatimagene plus radiation therapy versus placebo plus radiation therapy (p=0.0155; HR 0.70; 95% CI; 0.52 to 0.94) ¹. Median DFS was not reached for the aglatimagene treatment arm versus 86.1 months in the placebo arm ¹. In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation for aglatimagene for this indication ¹. In March 2025, the company announced overall survival data from its phase 2a clinical trial of aglatimagene in non-small cell lung cancer (NSCLC), with a median overall survival (mOS) of 24.5 months ¹ in patients receiving two aglatimagene plus valacyclovir courses (n=46) ¹. In February 2025, the final analysis of the phase 2a clinical trial of aglatimagene in borderline resectable pancreatic ductal adenocarcinoma (PDAC) showed an estimated mOS of 31.4 months ¹ in the aglatimagene group versus 12.5 months ¹ in the control group ¹. However, in October 2025, the company decided to pause further clinical development of aglatimagene in PDAC unless externally funded ¹. In January 2026, the company received clearance for an IND to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study of linoserpaturev in recurrent glioblastoma ¹.

Candel Therapeutics plans to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026 ¹. The company expects to announce supportive data on prostate cancer-specific outcomes, including prostate cancer-specific DFS, time to salvage anti-cancer therapy, and time to metastasis, after extended follow-up in the second quarter of 2026 ¹. Additionally, novel immunological biomarker data in localized prostate cancer is expected to be presented in the third quarter of 2026 ¹.

A major growth area for the company is the continued development of aglatimagene in stage III/IV NSCLC patients with inadequate responses to standard of care (SoC) immune checkpoint inhibitors (ICI). Based on positive phase 2a findings, the company plans to initiate a pivotal phase 3 clinical trial in patients with progressive, metastatic, non-squamous NSCLC despite ICI treatment in the second quarter of 2026 ¹. This study will randomize participants to two courses of aglatimagene plus valacyclovir plus continued ICI versus SoC docetaxel-based chemotherapy ¹. The company expects to announce updated data on overall survival (OS), including long-term survival and biomarker analysis, from the phase 2a clinical trial in the first quarter of 2026 ¹.

Another growth area involves linoserpaturev in recurrent high-grade glioma (HGG). The company recently obtained clearance for an Investigational New Drug (IND) application, which will support enabling work for a potential future randomized controlled phase 2 dose regimen finding study of linoserpaturev in recurrent glioblastoma ¹. This study aims to potentially identify the optimal dosing regimen and improve median overall survival (mOS) compared to SoC ¹. The company has completed recruitment for Arm C of the ongoing phase 1b clinical trial and expects to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026 ¹.

Operationally, Candel Therapeutics plans to implement a capital-efficient commercialization model for aglatimagene in prostate cancer, focusing on establishing strong relationships with leading investigators, high-volume treatment centers, patient advocacy organizations, and payers ¹. The company's manufacturing strategy involves relying on third-party contract manufacturers (CDMOs) for commercial-scale manufacturing of both aglatimagene and linoserpaturev ¹. For aglatimagene, the CDMO has scaled up the process and manufactured four successful large-scale runs, and a clinical batch using the commercial manufacturing process has been produced for future clinical trials ¹. The selected CDMO is preparing to validate the commercial manufacturing process by executing process validation batches to enable a BLA filing ¹. The company expects its cost-of-goods to be substantially lower than cell- and antibody-based therapies due to its high-yield manufacturing process ¹.

The company's enLIGHTEN™ Discovery Platform is expected to enable rapid vector engineering, generating new candidates in a data-driven and indication-specific manner using computational biology and artificial intelligence ¹. This platform leverages the high capacity of HSV for genetic cargo to introduce large genetic cargos, such as multiple immunomodulatory genes, to enhance anti-tumor immune responses ¹.

Candel Therapeutics intends to establish strategic partnerships to maximize the value of its current and future product candidates, potentially pairing aglatimagene, linoserpaturev, and future product candidates with other novel agents owned by strategic partners ¹. These partnerships may also help realize the full potential of product candidates in markets where the company is unlikely to pursue development or commercialization independently ¹. The company intends to maintain significant economic interest in its product candidates and selectively consider partnership opportunities ¹.

The company expects that its existing cash and cash equivalents, together with the net proceeds from the February 2026 equity offering of approximately $93.5 million ², will be sufficient to fund its current operating plan into the first quarter of 2028 ². The company's future capital requirements are dependent on the scope, progress, results, and costs of product discovery, preclinical and clinical development, and manufacturing ².

Candel Therapeutics faces numerous material risks, including its limited operating history and lack of product sales revenue, with expected significant expenses and increasing operating losses for the foreseeable future ². The company will need substantial additional funding, and if capital is unavailable on acceptable terms, it may be forced to delay, reduce, or eliminate product development or commercialization efforts, or cease operations ². Indebtedness, including a $50.0 million ² loan outstanding under a $130.0 million ² term loan facility with Trinity, could adversely affect financial condition, increase vulnerability to economic conditions, and limit financial flexibility ². The RTW Purchase Agreement, which provides $100.0 million ² upon marketing approval of aglatimagene for prostate cancer in exchange for tiered royalties up to $250.0 million ², imposes covenants that restrict operating and financial flexibility, and non-compliance could harm results ². Adverse developments in the financial services industry, such as liquidity issues or defaults by financial institutions, could impair access to funding and negatively impact business operations ². The business is highly dependent on the success of aglatimagene and linoserpaturev, which require additional development and may fail to demonstrate adequate safety and efficacy in clinical trials, leading to delays or denial of regulatory approval ². The novel approach of viral immunotherapy makes predicting development time and cost difficult, and earlier study results may not predict future trial success ². Undesirable side effects, such as flu-like symptoms and injection site reactions, have been observed in clinical trials, and more severe or unexpected side effects could delay or prevent approval ². Difficulty in patient enrollment, particularly for rare cancers like HGG, could delay clinical trials ². Even if approved, product candidates may not achieve broad market acceptance due to factors like efficacy, safety, pricing, and competition ². The regulatory approval processes are lengthy and unpredictable, and Fast Track, RMAT, or Orphan Drug Designations do not guarantee faster development or approval ². Post-approval, products are subject to extensive ongoing regulatory review, which may result in significant additional expense and limit commercialization ². The company faces substantial competition from major pharmaceutical and biotechnology companies with greater resources ². Failure to establish sales, marketing, and patient support capabilities, or to secure adequate third-party reimbursement, could limit revenue ². Reliance on third-party collaborators and manufacturers exposes the company to risks of non-performance, delays, or non-compliance with regulations like cGMP, which could jeopardize product supply and development timelines ². Employee misconduct, cybersecurity incidents, data breaches, and natural disasters or geopolitical conflicts could disrupt operations, cause reputational damage, and incur significant liabilities ². Changes in tax laws or their interpretation, such as those under the One Big Beautiful Bill Act of 2025 (OBBBA), could adversely affect financial condition, and the ability to utilize net operating loss carryforwards may be limited by ownership changes ².

Management's message to shareholders emphasizes the company's commitment to developing first-in-class and best-in-class biological multimodal immunotherapies to transform cancer patient lives. They highlight the positive topline data from the pivotal phase 3 clinical trial of aglatimagene in newly diagnosed, localized prostate cancer, which demonstrated a statistically significant improvement in disease-free survival (DFS) (p=0.0155; HR 0.70; 95% CI; 0.52 to 0.94) ¹. Management plans to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026 ¹, believing it could be the first new FDA-approved pharmacologic treatment for this patient population in over 20 years ¹. They also underscore the promising overall survival data from the phase 2a clinical trial of aglatimagene in non-small cell lung cancer (NSCLC), with a median overall survival (mOS) of 24.5 months ¹ in patients receiving two aglatimagene plus valacyclovir courses ¹, leading to plans for a pivotal phase 3 clinical trial in NSCLC in the second quarter of 2026 ¹. A key strategic priority is to leverage the enLIGHTEN™ Discovery Platform for rapid vector engineering and new candidate generation using computational biology and artificial intelligence ¹. Management also stresses the importance of establishing strategic partnerships to maximize product candidate value and ensuring commercial-scale manufacturing through third-party contract manufacturers, expecting substantially lower cost-of-goods due to high-yield processes ¹. The company expects its existing cash and cash equivalents, combined with net proceeds from the February 2026 equity offering of approximately $93.5 million ², to fund operations into the first quarter of 2028 ².